G1 Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de G1 Therapeutics' es Jack Bailey , nombrado en Jan 2021, tiene una permanencia de 3.25 años. compensación anual total es $3.25M, compuesta por 24.5% salario y 75.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.28% de las acciones de la empresa, por valor de $540.78K. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 5.6 años, respectivamente.
Información clave
Jack Bailey
Chief Executive Officer (CEO)
US$3.3m
Compensación total
| Porcentaje del salario del CEO | 24.5% |
| Permanencia del CEO | 3.3yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 3.3yrs |
| Promedio de permanencia en la Junta Directiva | 5.7yrs |
Actualizaciones recientes de la dirección
Recent updates
G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 04
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
Mar 22Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge
Feb 27Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?
Feb 06G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry
Jan 04Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
Jun 08New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)
May 08The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts
Nov 04G1 Therapeutics: Catalysts Stacking
Oct 20G1 Therapeutics: Building A Franchise
Sep 29Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)
Aug 04G1 Therapeutics Q2 2022 Earnings Preview
Aug 02G1 Therapeutics: Take Advantage Of The November Data
Jul 22G1 Therapeutics granted regulatory nod for cancer therapy in China
Jul 13G1 Therapeutics: Needs To Expand Labels And Commercialize Better
Apr 27Health Check: How Prudently Does G1 Therapeutics (NASDAQ:GTHX) Use Debt?
Apr 19G1 Therapeutics: Biotech With FDA Approved Drug Plus Additional Potential
Feb 08G1 Therapeutics (NASDAQ:GTHX) Has Debt But No Earnings; Should You Worry?
Dec 07G1 Therapeutics: Market May Be Terribly Underestimating This Company
Nov 20G1 Therapeutics (NASDAQ:GTHX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 03Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$31m |
| Dec 31 2023 | US$3m | US$795k | -US$48m |
| Sep 30 2023 | n/a | n/a | -US$71m |
| Jun 30 2023 | n/a | n/a | -US$78m |
| Mar 31 2023 | n/a | n/a | -US$126m |
| Dec 31 2022 | US$3m | US$764k | -US$148m |
| Sep 30 2022 | n/a | n/a | -US$154m |
| Jun 30 2022 | n/a | n/a | -US$171m |
| Mar 31 2022 | n/a | n/a | -US$171m |
| Dec 31 2021 | US$9m | US$735k | -US$148m |
| Sep 30 2021 | n/a | n/a | -US$134m |
| Jun 30 2021 | n/a | n/a | -US$103m |
| Mar 31 2021 | n/a | n/a | -US$95m |
| Dec 31 2020 | US$2m | n/a | -US$99m |
Compensación vs. Mercado: La compensación total de Jack($USD3.02M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.63M).
Compensación vs. Ingresos: La compensación de Jack ha aumentado mientras la empresa no es rentable.
CEO
Jack Bailey (58 yo)
3.3yrs
Permanencia
US$3,250,658
Compensación
Mr. John E. Bailey, also known as Jack, Jr. has been Director at G1 Therapeutics, Inc. since March 12, 2020. He serves as President and Chief Executive Officer at G1 Therapeutics Inc. since January 1, 2021...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 3.3yrs | US$3.25m | 0.28% $ 617.8k | |
| Chief Medical Officer | 9.8yrs | US$1.11m | 0.14% $ 320.7k | |
| Chief Business Officer | 4.8yrs | US$1.17m | 0.027% $ 59.0k | |
| Chief Financial Officer | 1.2yrs | sin datos | 0.018% $ 40.0k | |
| Chief Operating Officer | 5.3yrs | US$2.75m | 0.018% $ 39.0k | |
| Vice President of Investor Relations & Corporate Communications | 3.3yrs | sin datos | sin datos | |
| Chief Legal & People Officer | less than a year | sin datos | 0.00034% $ 755.5 | |
| Vice President of Marketing | no data | sin datos | sin datos | |
| Chief Commercial Officer | 2.8yrs | US$3.39m | 0.0066% $ 14.7k | |
| Senior Director of Investor Relations & Corporate Communications | no data | sin datos | sin datos |
3.3yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de GTHX se considera experimentado (3.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 4.2yrs | US$3.25m | 0.28% $ 617.8k | |
| Member of Clinical Advisory Board | no data | US$456.29k | sin datos | |
| Independent Director | 8.7yrs | US$172.85k | 0.35% $ 787.8k | |
| Scientific & Clinical Advisor | no data | sin datos | sin datos | |
| Scientific & Clinical Advisor | no data | sin datos | sin datos | |
| Independent Director | 5.9yrs | US$162.85k | 0.030% $ 67.5k | |
| Independent Chairman of the Board | 5.7yrs | US$195.35k | 0.028% $ 61.1k | |
| Scientific & Clinical Advisor | no data | sin datos | sin datos | |
| Director | 1.8yrs | US$135.35k | 0% $ 0 | |
| Co-Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Scientific & Clinical Advisor | no data | sin datos | sin datos | |
| Scientific & Clinical Advisor | no data | sin datos | sin datos |
5.7yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de GTHX se considera experimentada (5.6 años de antigüedad promedio).